(9-110) Efficacy and Safety of Fixed Versus Weight-Based Factor Eight Inhibitor Bypassing Activity (FEIBA) for Apixaban or Rivaroxaban Associated Intracranial Hemorrhage
Wednesday, December 10, 2025
8:30 AM - 9:30 AM
Location: Bayside A, Level 1
Residency Program: Community Regional Medical Center Residency Program Type: PGY1 (Pharmacy) Residency Program Location: California
